Mineralys Therapeutics (MLYS) vs Zymeworks (ZYME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Zymeworks (ZYME) has outperformed Mineralys Therapeutics (MLYS) over the past year, gaining 60.8% versus a loss of 41.3%. Mineralys Therapeutics is the larger company by market cap ($1.95 billion vs $1.90 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MLYS | ZYME |
|---|---|---|
| Share price | $22.09 | $26.53 |
| Market cap | $1.95B | $1.90B |
| 1-day change | +0.64% | +3.43% |
| YTD return | -39.13% | +0.76% |
| 1-year return | -41.34% | +60.79% |
| 5-year return | — | +2.27% |
| Forward P/E | — | 30.43 |
| EPS (TTM) | $-4.22 | $-2.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $47.65 | $31.34 |
| 52-week low | $21.50 | $16.00 |
| Distance from 52-week high | -53.64% | -15.35% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +119.56% | +55.33% |
| Average volume | 1.03M | 673.06K |
| Shares outstanding | 88.41M | 71.20M |
| Employees | 76 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZYME has outperformed MLYS by 102.1 percentage points over the past year.
About Mineralys Therapeutics
MLYS stock →Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
About Zymeworks
ZYME stock →Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
MLYS vs ZYME FAQ
Which is bigger, Mineralys Therapeutics or Zymeworks?
Mineralys Therapeutics (MLYS) is larger, with a market capitalization of $1.95B compared with $1.90B for Zymeworks (ZYME).
Which stock has performed better over the past year, MLYS or ZYME?
ZYME returned +60.79% over the past 12 months, compared with -41.34% for MLYS (price return, excluding dividends). Past performance does not predict future results.
Are Mineralys Therapeutics and Zymeworks in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.